MALARIA VACCINE

It is challenging to develop a malaria vaccine. It is technically challenging to create a vaccine against a parasite that has two hostsmosquitoes and humans.

Additionally, several pharmaceutical firms have shown interest in creating a malaria vaccine.

The individuals who need a malaria vaccine the most reside in some of the world's poorest nations, despite the fact that travelers to afflicted areas may benefit from a malaria immunization. As a consequence, developing a vaccine is not financially rewarding.

More than 30 years of research went into the creation of Mosquirix, which was created in partnership between GlaxoSmithKline (GSK) and the Walter Reed Army Institute of Research in the US.

Given that both the antigen design and the adjuvant strategy were unique, this period seems acceptable.

Dettagli